RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Wayne W. Harding to Molecular Structure

This is a "connection" page, showing publications Wayne W. Harding has written about Molecular Structure.
Connection Strength

1.437
  1. Cordone P, Namballa HK, Muniz B, Pal RK, Gallicchio E, Harding WW. New tetrahydroisoquinoline-based D3R ligands with an o-xylenyl linker motif. Bioorg Med Chem Lett. 2021 06 15; 42:128047.
    View in: PubMed
    Score: 0.176
  2. Karki A, Namballa HK, Alberts I, Harding WW. Structural manipulation of aporphines via C10 nitrogenation leads to the identification of new 5-HT7AR ligands. Bioorg Med Chem. 2020 08 01; 28(15):115578.
    View in: PubMed
    Score: 0.166
  3. Giri R, Namballa HK, Sarker A, Alberts I, Harding WW. Synthesis and dopamine receptor pharmacological evaluations on ring C ortho halogenated 1-phenylbenzazepines. Bioorg Med Chem Lett. 2020 08 15; 30(16):127305.
    View in: PubMed
    Score: 0.166
  4. Karki A, Juarez R, Namballa HK, Alberts I, Harding WW. Identification of C10 nitrogen-containing aporphines with dopamine D1 versus D5 receptor selectivity. Bioorg Med Chem Lett. 2020 04 15; 30(8):127053.
    View in: PubMed
    Score: 0.163
  5. Kapadia N, Ahmed S, Harding WW. New halogenated tris-(phenylalkyl)amines as h5-HT2B receptor ligands. Bioorg Med Chem Lett. 2016 07 15; 26(14):3216-3219.
    View in: PubMed
    Score: 0.126
  6. Kapadia N, Harding WW. C4 phenyl aporphines with selective h5-HT(2B) receptor affinity. Bioorg Med Chem Lett. 2015 Sep 01; 25(17):3451-4.
    View in: PubMed
    Score: 0.118
  7. Madapa S, Harding WW. Semisynthetic Studies on and Biological Evaluation of N-Methyllaurotetanine Analogues as Ligands for 5-HT Receptors. J Nat Prod. 2015 Apr 24; 78(4):722-9.
    View in: PubMed
    Score: 0.115
  8. Ponnala S, Gonzales J, Kapadia N, Navarro HA, Harding WW. Evaluation of structural effects on 5-HT(2A) receptor antagonism by aporphines: identification of a new aporphine with 5-HT(2A) antagonist activity. Bioorg Med Chem Lett. 2014 Apr 01; 24(7):1664-7.
    View in: PubMed
    Score: 0.108
  9. Pecic S, McAnuff MA, Harding WW. Nantenine as an acetylcholinesterase inhibitor: SAR, enzyme kinetics and molecular modeling investigations. J Enzyme Inhib Med Chem. 2011 Feb; 26(1):46-55.
    View in: PubMed
    Score: 0.083
  10. Chaudhary S, Pecic S, Legendre O, Navarro HA, Harding WW. (+/-)-Nantenine analogs as antagonists at human 5-HT(2A) receptors: C1 and flexible congeners. Bioorg Med Chem Lett. 2009 May 01; 19(9):2530-2.
    View in: PubMed
    Score: 0.076
  11. Harding WW, Schmidt M, Tidgewell K, Kannan P, Holden KG, Dersch CM, Rothman RB, Prisinzano TE. Synthetic studies of neoclerodane diterpenes from Salvia divinorum: selective modification of the furan ring. Bioorg Med Chem Lett. 2006 Jun 15; 16(12):3170-4.
    View in: PubMed
    Score: 0.062
  12. Harding WW, Schmidt M, Tidgewell K, Kannan P, Holden KG, Gilmour B, Navarro H, Rothman RB, Prisinzano TE. Synthetic studies of neoclerodane diterpenes from Salvia divinorum: semisynthesis of salvinicins A and B and other chemical transformations of salvinorin A. J Nat Prod. 2006 Jan; 69(1):107-12.
    View in: PubMed
    Score: 0.061
  13. Simpson DS, Katavic PL, Lozama A, Harding WW, Parrish D, Deschamps JR, Dersch CM, Partilla JS, Rothman RB, Navarro H, Prisinzano TE. Synthetic studies of neoclerodane diterpenes from Salvia divinorum: preparation and opioid receptor activity of salvinicin analogues. J Med Chem. 2007 Jul 26; 50(15):3596-603.
    View in: PubMed
    Score: 0.017
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support